Abstracts Archive - Page 1989 of 2607 - ACR Meeting Abstracts

Abstract Number: 1774 • 2015 ACR/ARHP Annual Meeting
Bone Marrow Derived Dendritic Cells Modified By Lentiviral-Mediated RelB shRNA Possess Tolerogenic Phenotype and Functions on Lupus Splenic Lymphocytes
Haijing Wu, Yi Lo, Albert Chan and Mo Yin Mok, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by high morbidity and mortality and remains challenging in treatment. Dendritic cells (DCs)…
Abstract Number: 1775 • 2015 ACR/ARHP Annual Meeting
Fn14 Deficiency Protects Lupus-Prone Mice from Cutaneous Lesions Induced By Ultraviolet B (UVB) Irradiation
Jessica Doerner¹, Adam Friedman², Linda Burkly³ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Department of Dermatology, George Washington School of Medicine and Health Sciences, Washington, DC, ³Biogen Idec, Cambridge, MA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Sunlight, via ultraviolet B (UVB) irradiation, is a well-recognized trigger of cutaneous lupus erythematosus (CLE) skin lesions. TNF-like weak inducer of apoptosis (TWEAK), a…
Abstract Number: 1776 • 2015 ACR/ARHP Annual Meeting
Significantly Reduced Lymphadenopathy, Salivary Gland Infiltrates and Proteinuria in MRL-Lpr/Lpr Mice Treated with Ultrasoluble Curcumin/Turmeric: Increased Survival with Curcumin Treatment
Biji T Kurien^1,2,3, Valerie M Harris^1,4, Syed MS Quadri^1,4, Patricia Coutinho-de Souza¹, Joshua Cavett^5,6, Amanda Moyer⁴, Bilal Ittiq⁷, Angela Metcalf⁶, Husayn Ramji⁸, Dat Truong⁸, Kristi A. Koelsch^4,9,10, Mike Centola¹¹, Adam Payne¹², D. Danda¹³ and R. Hal Scofield^1,14, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Allergy and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷University of Oklahoma Health Sciences Center, Oklahoma, OK, ⁸University of Oklahoma, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ¹⁰Department Veterans Affairs Medical Center, Oklahoma City, OK, ¹¹Haus Bioceuticals, Oklahoma City, OK, ¹²Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ¹³Christian Medical College, Vellore, India, ¹⁴US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Commercial curcumin (CU), derived from food spice turmeric, has been widely studied as a potential therapeutic for a variety of oncological and inflammatory conditions.…
Abstract Number: 1777 • 2015 ACR/ARHP Annual Meeting
Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
Li Chun Wang¹, Stuart Perper¹, Kimberly Black¹, Regina Mario¹, Candace Graff^2,3, Dawna Hartman³, Andrew Souers⁴, Steven Elmore⁴ and Lisa Olson^1,3, ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. We report here that continuous daily treatment with 30mpk venetoclax…
Abstract Number: 1778 • 2015 ACR/ARHP Annual Meeting
Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis
Jeffrey Hampton¹, Nicholas A. Young², Sudha Agarwal³, Saba Aqel³, Kendra Jones³, Lai-Chu Wu^2,4, Nicole Powell⁵, John Sheridan⁵, Michael Bruss³ and Wael N. Jarjour², ¹Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, ⁵Institute for Behavioral Medicine Research, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Chronic inflammation is pathognomonic of autoimmune diseases and contributes to organ damage. Our group has previously shown that moderate daily exercise reduces systemic inflammation…
Abstract Number: 1779 • 2015 ACR/ARHP Annual Meeting
Characterization of Anti-Nuclear Antibody (ANA) Signatures in Murine Models of Lupus Using Genalyte Maverick Technology
Jacqueline Loud¹, Stuart Perper², Rachel Twomey² and Stephen Clarke², ¹Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Pharmacology, Abbvie Bioresearch Center Inc., Worcester, MA
Background/Purpose: Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are autoimmune diseases characterized by circulating antibodies to nuclear self-antigens, including reactivities to double-stranded DNA, RNP…
Abstract Number: 1780 • 2015 ACR/ARHP Annual Meeting
Oxidative Stress Protects Against Nephritis Induced By Chronic Graft Versus Host Disease
Zachary Oaks¹, Adam Bartos², Miguel Beckford³, Mark Haas⁴ and Andras Perl⁵, ¹Medicine, SUNY Upstate, Syracuse, NY, ²Medicine, SUNY, Syracuse, NY, ³SUNY Upstate, Syracuse, NY, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Department of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by glutathione depletion and oxidative stress in T cells which lead to abnormal lineage development and dysfunction. In…
Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting
Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea
Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
Abstract Number: 1782 • 2015 ACR/ARHP Annual Meeting
a Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan
Naoto Yokogawa¹, Toshiya Takahashi², Toshiaki Sato³ and Naohisa Yokota⁴, ¹on behalf of Japanese Hydroxychloroquine Study Group, Japan, Japan, ²Sanofi K.K., Tokyo, Japan, ³Sanofi.KK, Tokyo, Japan, ⁴Sanofi KK, Tokyo, Japan
Background/Purpose: In Japan hydroxychloroquine (HCQ) is still unavailable due to the banning of chloroquine in 1974 following allegations that it caused severe retinopathy. Therefore, a…
Abstract Number: 1783 • 2015 ACR/ARHP Annual Meeting
Dietary Fish Oil Supplementation Raises Serum Essential Fatty Acid Concentrations in Patients with Systemic Lupus Erythematosus and Correlates with Improvements in Inflammation and Pain
Cristina Arriens¹, Carlos Rodriguez-Navas², David R. Karp¹, Jeffrey McDonald² and Chandra Mohan³, ¹Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ²Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, ³Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: A comprehensive metabolomic screen comparing sera from patients with systemic lupus erythematosus (SLE) to healthy controls (HC) indicated a relative deficiency in omega-3 fatty…
Abstract Number: 1784 • 2015 ACR/ARHP Annual Meeting
Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine
Johanna Nagel¹, Tore Saxne², Pierre Geborek³, Anders A. Bengtsson⁴, Søren Jacobsen⁵, Charlotte Sværke Jørgensen⁶, Andreas Jönsen⁷ and Meliha C. Kapetanovic³, ¹Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ²Dept of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology Lund University and Skåne University Hospital, Lund, Sweden, ⁴Rheumatology, Inst of Clinical sciences, Lund, Sweden, ⁵Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁶Department of Microbiological Diagnostics & Virology, Statens Serum Institut, Copenhagen, Denmark, ⁷Department of Rheumatology, Lund University Hospital, Lund, Sweden
Background/Purpose: To explore the impact of SLE disease and belimumab given in addition to standard of care therapy on antibody response after vaccination with PCV13…
Abstract Number: 1785 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Relative Factors of Infections in Southern Chinese Patients with Systemic Lupus Erythematosus
Zhongping Zhan, Dongying Chen, Qian Qiu and Liuqin Liang, Department of Rheumatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background/Purpose: To determine the clinical characteristics and to identify relative factors of infection in patients with Systemic Lupus Erythematosus, to provide a data for making…
Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Vibeke Strand¹, Annette Diehl², Jared Christensen², Joseph Wajdula², Sudhakar Sridharan³ and Paul J Healey², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, New York City, NY, ³PPD Inc, Rockville, MA
Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…
Abstract Number: 1787 • 2015 ACR/ARHP Annual Meeting
Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Monica Purmalek¹, Simantini Sakhardande¹, Yenealem Temesgen-Oyelakin², Alice Fike³, Taufiq Salahuddin⁴, Balaji Natarajan⁴, Zerai Manna², Elizabeth Joyal², Sarfaraz Hasni², Nehal N. Mehta⁴ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, compared to…
Abstract Number: 1788 • 2015 ACR/ARHP Annual Meeting
Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Simantini Sakhardande¹, Monica Purmalek¹, Maureen Sampson², Yenealem Temesgen-Oyelakim³, Alice Fike⁴, Taufiq Salahuddin⁵, Balaji Natarajan⁵, Zerai Manna⁶, Elizabeth Joyal⁶, Marcus Chen⁵, Sarfaraz Hasni⁶, Nehal N. Mehta^5,7, Alan Remaley⁵ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²CC/NIH, Bethesda, MD, ³Office of the Clinical Director,National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵NHLBI, National Institutes of Health, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Risk of atherosclerotic cardiovascular disease (CVD) is significantly enhanced in systemic lupus erythematosus (SLE) compared to age and gender matched controls. While this risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].